In particular, Aradhye noted "increasing progress" at all levels of the innovation supply chain in China — "whether it's ...

Novartis has agreed to partner on developing additional molecular glue degraders (MGDs) for immune-mediated diseases, in an expanded collaboration that could generate more than $5.7 billion for the ...

Structurally-guided discovery using high-resolution cryo-EM has delivered potent, DCAF16-dependent Targeted Glues™ of SMARCA2, with exquisite ...

British pharmaceutical giant GSK committed to investing at least $30 billion in U.S. research and developing and ...

In all, 1,088 bottles of Chasselas wine were uncorked simultaneously in the Swiss village of Chardonne on Saturday.

Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics agreed to an up to $5.7 billion licensing deal to develop ...

Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to US$5.7 billion on ...

Monte Rosa stock soars 38% after a $5.7B Novartis partnership to develop AI-powered degraders for immune diseases. Read more ...

The new projects, including AI efforts in Pennsylvania and three other states, are part of the British firm's pledge to ...

We need not consider whether Novartis would suffer irreparable injury because it cannot demonstrate ‘certainty of success on ...

Get the latest healthcare market updates, stock performance, and key pharma news, including Trump’s drug price push and major ...

Shares of Monte Rosa Therapeutics jumped in premarket trading Monday after it said it will partner with Swiss pharmaceutical company Novartis to develop a degrader-based drug to treat immune-mediated ...